Organon & Co / Organon Forei
Organon & Co is an American healthcare company focused on women's health, biosimilars, and established prescription pharmaceuticals. Spun off from Merck & Co, the company manufactures and markets reproductive health therapeutics, contraception solutions including Nexplanon, biosimilars, and mature brand cardiovascular and respiratory treatments. Main revenue drivers consist of global commercial sales of women's healthcare products, biosimilar pharmaceuticals, and established branded prescription drugs. Organon serves gynecologists, primary care physicians, hospital networks, prescription pharmacies, and patients globally. The company holds a market-leading global position in women's reproductive health and contraceptive therapies. Headquartered in Jersey City, New Jersey, Organon & Co is listed on the New York Stock Exchange.
8 of the funds FundTelligence covers report a position in Organon & Co / Organon Forei.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 8
Funds holding Organon & Co / Organon Forei
- Nordea Low Duration US High Yield — Nordea Funds · 0.56 % (full portfolio disclosed, September 2026)
- Danske Invest Euro High Yield Obligasjon — Danske Invest · 0.27 % (full portfolio disclosed, September 2026)
- Nordea Corporate Bond Fund 1-3 Years — Nordea Funds · 0.26 % (full portfolio disclosed, September 2026)
- Nordea US Corporate Sustainable Stars Bond Fund — Nordea Funds · 0.22 % (full portfolio disclosed, September 2026)
- Nordea Virksomhedsobligationer Højrente — Nordea Funds · 0.14 % (full portfolio disclosed, September 2026)
- Nordea Global High Yield Sustainable Stars Bond Fund — Nordea Funds · 0.14 % (full portfolio disclosed, September 2026)
- Nordea Global High Yield Enhanced Bond Fund — Nordea Funds · 0.11 % (full portfolio disclosed, September 2026)
- Nordea Global High Yield Bond Fund — Nordea Funds · 0.09 % (full portfolio disclosed, September 2026)